Drug-induced lupus
Drug-induced lupus
复制标题
DOI：
10.1196/annals.1422.019
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Gershwin, M. Eric
中科院分区：
文献类型：
--
作者：
Borchers, Andrea T.;Keen, Carl L.;Gershwin, M. Eric
药物性狼疮（DIL）是一种罕见的对多种药物的不良反应，其特征与特发性系统性红斑狼疮（SLE）相似。它通常只在几个月后发展，通常是几年的治疗后才发展，尽管在某些情况下，潜伏期为几天或几周。有一些迹象表明，随着每日剂量和累积剂量的增加以及治疗时间的延长，DIL的风险会增加。对于DIL没有明确的和普遍接受的诊断标准，但提出了以下指南：(a)充分和持续地暴露于特定药物，(b)至少有一种与SLE相一致的症状，(e)在开始使用该药物之前没有提示SLE的病史，(d)在停药后几周（有时是几个月）症状消退。此外，经常有人认为，ANA的存在是诊断DIL所必需的。然而，阴性ANA检测结果不应自动排除这种诊断，特别是如果患者有与SLE/DIL相关的其他自身抗体。
Drug-induced lupus (DIL) is a rare adverse reaction to a large variety of drugs with features resembling those of idiopathic systemic lupus erythernatosus (SLE). It usually develops only after months and, quite commonly, years of treatment with the offending agent, although latencies of days or weeks have been described in some instances. There are some indications that the risk of DIL can increase with higher daily and cumulative doses and with longer duration of therapy. There are no definitive and commonly accepted diagnostic criteria for DIL, but the following guidelines have been proposed: (a) sufficient and continuing exposure to a specific drug, (b) at least one symptom compatible with SLE, (e) no history suggestive of SLE before starting the drug, and (d) resolution of symptoms within weeks (sometimes months) after discontinuation of the putative offending agent. In addition, it is frequently suggested that the presence of ANA is required for the diagnosis of DIL. However, negative ANA test results should not automatically preclude such a diagnosis, particularly if a patient has other autoantibodies associated with SLE/DIL.